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Background: Although recent animal studies have suggested that angiopoietin-like protein 2 (ANGPTL2), a novel
inflammatory adipokine, is likely to be involved in the pathogenesis of atherosclerosis, in rodents, little is known regarding
whether serum ANGPTL2 level is also associated with atherosclerosis in humans, especially in patients with type 2
diabetes. The aim of this study was to investigate whether serum ANGPTL2 concentration is associated with atherosclerosis
by measuring carotid intima-media thickness (IMT) in subjects with type 2 diabetes without previous history of cardiovascular
diseases. In addition, we examined the clinical and biochemical variables associated with serum ANGPLT2 concentration.
Methods:We measured the circulating ANGPTL2 level in 166 subjects (92 men and 74 women; mean age of 60.0
years) with type 2 diabetes. Measurements of carotid IMT were performed in all subjects.
Results: Serum ANGPTL2 concentration was positively correlated with carotid IMT (r = 0.220, p= 0.004). In multiple linear
regression, serum ANGPTL2 concentration was independently associated with increased carotid IMT along with older age,
male gender, and higher systolic blood pressure. Higher levels of hemoglobin A1c and high-sensitivity C-reactive protein
were significantly associated with elevated serum ANGPTL2 concentration in subjects with type 2 diabetes.
Conclusions: Serum ANGPTL2 concentration was significantly and positively associated with carotid atherosclerosis in
patients with type 2 diabetes, suggesting that ANGPTL2 may be important in the atherosclerosis in humans.
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Obesity is now clearly associated with a state of chronic
low-grade inflammation characterized by abnormal cyto-
kine production and activation of inflammatory signaling
pathways in adipose tissues, which contributes to insulin
resistance [1]. Angiopoietin is a part of a family of vas-
cular growth factors that are important modulators of
angiogenesis [2]. A family of proteins structurally similar
to angiopoietin was identified and designated as ‘angio-
poietin-like proteins (ANGPTLs)’ [3-7]. Encoded by* Correspondence: jypark@amc.seoul.kr
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unless otherwise stated.eight genes, ANGPTL1-8 are structurally similar to
angiopoietins, characterized by a coiled-coil domain in
the N-terminus and a fibrinogen-like domain in the C-
terminus, except for ANGPTL8 which does not have a
fibrinogen-like domain [3-7]. However, ANGPTLs do
not bind to angiopoietin receptors, (i.e., either Tie2 or
the related protein Tie1), suggesting that these ligands
function differently from angiopoietins [6,8,9]. Several
studies have reported that a subset of ANGPTLs func-
tion in glucose, lipid, and energy metabolism, although
they mainly regulate angiogenesis [3,7].
Among ANGPTLs, ANGPTL2 is abundantly expressed
in visceral adipose tissue and has been demonstrated to be
involved in adipose tissue remodeling, such as angiogen-
esis and extracellular matrix remodeling, ultimately lead-
ing to adipogenesis and adipocyte hypertrophy, increasing
excess energy storage in adipose tissue [4,10]. In cases ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pose tissues and excess signaling by ANGPTLs leads to
chronic inflammation, resulting in metabolic diseases such
as obesity-related insulin resistance and type 2 diabetes
[4,10]. Besides its metabolic role, ANGPTL2 has grow-
ingly received attention due to its deleterious effect on
atherosclerotic diseases [9-14]. In a mouse model,
ANGPTL2-deficient animals showed decreased abdominal
aortic aneurysms, characterized pathologically by athero-
sclerotic changes accompanying chronic inflammation
and infiltrating inflammatory cells [13]. In addition, peri-
vascular ANGPTL2 accelerates neointimal hyperplasia
after endovascular injury in mice [12]. Recently, disruption
of ANGPTL2 in apolipoprotein E-deficient mice (ApoE-/-/
Angptl2-/-) was found to attenuate atherosclerosis progres-
sion by decreasing the number of macrophage infiltrating
atheromatous plaques, thereby reducing vascular inflam-
mation [9]. Although these findings support the concept
that ANGPTL2 is more likely to be involved in the regula-
tion of vascular function, more specifically in atheroscler-
osis in rodents [9,10,12-14], few studies have examined
the relevance of circulating ANGPTL2 levels to subclinical
atherosclerosis in humans [9]. Furthermore, it remains un-
clear about to what extent ANGPTL2 contributes to the
development of atherosclerosis independently of conven-
tional cardiovascular risk factors, especially in subjects
with type 2 diabetes.
In our current study, we investigated whether serum
ANGPTL2 concentration was associated with the parame-
ters of atherosclerosis in subjects with type 2 diabetes
using carotid artery intima-media thickness (IMT), a non-
invasive index of early atherosclerosis [15]. In addition, we
tried to identify the clinical and biochemical variables re-
lated to the serum concentration of ANGPTL2.
Methods
Study populations
As previously described [16], we consecutively recruited
patients who visited the Asan Diabetes Center at Asan
Medical Center (AMC), Seoul, Republic of Korea between
November 2012 and January 2014 for treatment of diabetes
and evaluation of micro- and macrovascular complications
of diabetes. Before starting the recruitment process, the
study was registered at the Clinical Research Information
Service (cris.nih.go.kr) (KCT0000598). Our study popula-
tion comprised 203 subjects who had undergone carotid
artery ultrasonography during recruitment.
A single specially trained nurse interviewed all partici-
pants and obtained information on medications and his-
tory of previous medical or surgical diseases. A history of
cardiovascular disease (CVD) was defined as a history of
physician-diagnosed CVD (eg, previous myocardial infarc-
tion, angina, coronary-artery bypass grafting, and/or
stroke). After exclusion of subjects with a history of CVD(n = 37), a total of 166 subjects (92 men aged 38-78 years
[mean age, 59.7 years] and 74 women aged 38-76 years
[mean age, 60.4 years]) with type 2 diabetes were included
in the study. All subjects provided written informed con-
sent and the study was approved by the Institutional
Review Board of the AMC.
Antidiabetic treatments were categorized as none, oral
hypoglycemic agents (OHAs), or insulin with or without
OHAs. Peroxisome proliferator-activated receptor γ ago-
nists such as thiazolidinedione affect the expression of
ANGPTL2 [10], therefore patients treated with thiazolidi-
nedione were excluded from the study prior to the initiation
of the recruitment process. Antihypertensive medications
included any of the following: angiotensin-converting en-
zyme inhibitors, angiotensin II receptor blockers, β-
blockers, calcium-channel blockers, diuretics, or α-blockers.Anthropometric and laboratory measurements
Height and weight were obtained while subjects wore
light clothing without shoes. The waist circumference
(WC, cm) was measured midway between the costal
margin and the iliac crest at the end of a normal expir-
ation. The blood pressure (BP) was measured on the
right arm after a rest of ≥5 min.
After overnight fasting, early morning blood samples
were drawn from the antecubital vein into vacuum tubes
and subsequently analyzed by a central, certified labora-
tory at the AMC. Measurements included fasting plasma
glucose (FPG), hemoglobin A1c (HbA1c), insulin, high-
sensitivity C-reactive protein (hsCRP), several lipid pa-
rameters, and liver enzyme levels.
FPG was measured by the glucose oxidase method using
a Toshiba 200FR Neo (Toshiba Medical Systems Co., Ltd.,
Tokyo, Japan). HbA1c was measured by high-performance
liquid chromatography (HPLC) using a Variant II Turbo
(Bio-Rad Laboratories, Hercules, CA). Fasting total choles-
terol, high-density lipoprotein-cholesterol (HDL-C), low-
density lipoprotein-cholesterol (LDL-C), triglyceride (TG),
uric acid, aspartate aminotransferase (AST), and alanine
aminotransferase (ALT) were measured using an enzym-
atic colorimetric method (Toshiba Medical Systems).
HsCRP was measured using the immunoturbidimetric
method (Toshiba Medical Systems). Serum insulin was
measured by immunoradiometric assay (TFB Co., Ltd,
Tokyo, Japan). Homeostatic model assessment of insulin
resistance (HOMA-IR) was used as a surrogate measure
of systemic insulin resistance, which has been suggested to
be a useful test for the evaluation of insulin resistance even
in patients with type 2 diabetes treated with an insulin se-
cretagogue or insulin [17,18]. All enzyme activities were
measured at 37°C. HOMA-IR was calculated according to
the following equation: HOMA-IR = [Insulin (μU/mL) ×
FPG (mmol/L)]/22.5.
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albumin-to-creatinine ratio (UACR), which was measured
by a photometric method using the Integra 800 system
(Roche Diagnostics, Indianapolis, IN) in a random spot
urine collection. Creatinine was measured using the Jaffe
method, and estimated glomerular filtration rate (eGFR)
was calculated using the modified Modification of Diet in
Renal Disease (MDRD) equation [19].Measurement of serum concentrations of ANGPTL 2 and
total adiponectin
Fasting venous blood samples were centrifuged, and the
supernatants were carefully collected to exclude cell com-
ponents. All samples with hemolysis or clotting were dis-
carded. Serum samples were stored at −80°C until use.
Serum ANGPTL2 concentrations were measured using a
human ANGPTL2 sandwich enzyme-linked immunosorb-
ent assay (ELISA) kit (Immuno-Biological Laboratories
Co., Ltd, Japan) with two mouse monoclonal antibodies
that were confirmed to recognize only ANGPTL2 and not
react with any other ANGPTLs or angiopoietins [10]. The
kit’s lower detection limit is typically less than 0.01 ng/ml.
The intra-and inter-assay coefficients of variations (CVs) of
the ELISA kit were <5.9% and <10.5%, respectively. Serum
total adiponectin concentration was also measured using
commercially available ELISA kits (Adipogen, Seoul, South
Korea), with intra-and inter-assay CVs of <4.0% and <6.0%,
respectively. Samples were assayed in duplicate and all re-
sults were reported as means.Ultrasonographic measurement of carotid IMT
Ultrasound analysis was performed by a single special-
ized technician who was blind to the patient's clinical
data. The examination was carried out according to a
previously established protocol standardized for both ca-
rotid arteries [20]. Images were acquired at end diastole
(defined as the R wave of the electrocardiogram) using a
5-12 MHz linear transducer and high resolution ultra-
sound (HD 11 XE, Philips Healthcare, Andover MA). All
measurements were recorded with the subject in a supine
position with the head elevated to 45° and tilted to either
side by 30°. The IMT was measured over a 1-cm segment
of the artery located approximately 0.5 cm below the
carotid-artery bulb and considered not to contain any
plaque (i.e., not to have any perceivable protrusion of the
artery wall into the lumen) [21,22]. For the purpose of the
present study, a QLAB IMT-quantification software meas-
urement plug-in (Philips Healthcare) was used to increase
the consistency and reliability of IMT measurements, re-
duce the effort required to successfully carry out IMT
measurements, and minimize the time needed to
complete an IMT study [23]. The correlation coefficient
for carotid IMT was 0.985. To quantify carotid artery wallthickness we used the mean of the right and left IMTs in
the present study.
Statistical analysis
Continuous variables with normal distribution were
expressed as mean ± SD, whereas continuous variables
with skewed distribution were expressed as median (and
interquartile range). Categorical variables were expressed
as proportions (%). The serum ANGPTL2 tertiles were
as follows: Q1 ≤ 3.27 ng/mL, Q2 = 3.28-5.19 ng/mL, and
Q3 ≥ 5.20 ng/mL. Demographic and biochemical charac-
teristics of the study population according to the serum
ANGPTL2 tertiles were compared using a one-way ana-
lysis of variance (ANOVA) with the Scheffe’s method as
a post-hoc analysis, or the Kruskal-Wallis test with the
Dunn procedure for continuous variables, and the chi-
squared test for categorical variables. The correlation be-
tween serum ANGPTL2 and various parameters, includ-
ing carotid IMT, was evaluated by Pearson correlation
analysis. Logarithmic (log) transformation of values
showing a skewed distribution was carried out before
the correlation analysis. The association between the
mean carotid IMT and serum ANGPTL2 level was in-
vestigated using backward multiple linear regression,
with mean carotid IMT serving as the dependent vari-
able. To identify the independent determinants of ca-
rotid IMT, univariate regression analysis was performed
as a preliminary step to a multiple linear regression. In
the multivariate model, all the variables that were associ-
ated with the carotid IMT with p values < 0.20 in the
univariate regression analysis were included. To identify
the factors contributing to increased serum ANGPTL2
levels, a backward multiple linear regression was per-
formed with serum ANGPTL2 levels serving as the
dependent variable. This analysis was adjusted for vari-
ables, which were associated with serum ANGPTL2 with
p values < 0.20 in the univariate regression analysis. All in-
dependent variables in the multiple linear regression ana-
lysis were tested for multicollinearity; if the variance
inflation factor (VIF) exceeded 10, the variable was con-
sidered to be collinear. All statistical analyses were carried
out with SPSS version 19.0 for Windows (IBM Corp.,
Armonk, NY). A two-tailed p-value < 0.05 was regarded as
statistically significant
Results
The average age of the study subjects was 60.0 ± 8.3
years, and about 60% of subjects were obese with a mean
BMI of 26.0 ± 3.4 kg/m2 [24]. The mean concentration
of serum ANGPTL2 was 4.75 ± 2.63 ng/ml. The clinical
and biochemical characteristics of the study subjects ac-
cording to the serum ANGPTL2 tertile are shown in
Table 1. A number of variables, including age, sex, BMI,
WC, systolic BP, diastolic BP, current smoker, duration
Table 1 Clinical biochemical characteristics of the study subjects according to the serum ANGPTL2 tertile
Serum ANGPTL2 tertile
Q1 Q2 Q3 P valuea
Variables (≤3.27ng/ml) (3.28 ~ 5.19 ng/ml) (≤5.20 ng/ml)
N 55 56 55 –
Age (years) 60.3 ± 7.1 60.8 ± 8.3 58.9 ± 9.4 0.429
Sex (male, %) 65.5 44.6 56.4 0.085
BMI (kg/m2) 25.3 ± 2.7 26.5 ± 3.6 26.2 ± 3.7 0.155
WC (cm) 88.4 ± 9.6 91.0 ± 9.0 90.2 ± 7.7 0.281
Systolic BP (mmHg) 126.9 ± 17.0 126.8 ± 15.5 128.4 ± 14.1 0.823
Diastolic BP (mmHg) 75.2 ± 9.1 74.6 ± 8.4 76.2 ± 8.5 0.625
Current smoker (%) 21.8 12.5 20.0 0.383
Duration of diabetes (years) 12 (4 − 14) 9 (6 − 14) 8 (4 − 13) 0.225
Antidiabetic medication (%) 0.400
None 7.3 1.8 7.3
OHA 74.5 85.7 81.8
Insulin ± OHA 18.2 12.5 10.9
Antihypertensive medication (%) 52.7 66.1 56.4 0.336
Statin use (%) 76.4 71.4 76.4 0.790
FPG (mmol/L) 7.4 ± 2.0b 7.8 ± 1.8b,c 8.2 ± 2.0c 0.042
HbA1c (%) 6.8 (6.4 − 7.2)b 7.0 (6.3 − 7.9)b,c 7.3 (6.7 − 8.2)c 0.047
HbA1c (mmol/mol) 51 (46 − 55)b 53 (45 − 63)b,c 56 (50 − 66)c 0.047
Total cholesterol (mmol/L) 4.1 ± 1.0 4.0 ± 0.8 4.0 ± 0.8 0.615
TG (mmol/L) 1.1 (0.9 − 2.1) 1.4 (1.1 − 2.2) 1.6 (1.1 − 2.4) 0.037
LDL-C (mmol/L) 2.5 ± 0.7 2.5 ± 0.7 2.5 ± 0.7 0.897
HDL-C (mmol/L) 1.3 ± 0.3b 1.2 ± 0.3b,c 1.1 ± 0.3c 0.036
Uric acid (μmol/L) 297.4 ± 89.2 285.5 ± 71.4 297.4 ± 71.4 0.781
AST (U/L) 21 (18 − 26) 23 (20 − 31) 23 (20 − 34) 0.079
ALT (U/L) 18 (14 − 25) 21 (16 − 38) 20 (15 − 33) 0.205
hsCRP (mg/L) 0.5 (0.1 − 1.1) 0.6 (0.3 − 1.1) 0.6 (0.4 − 1.6) 0.130
UACR (mg/g) 7.0 (4.0 − 24.8) 12.8 (5.7 − 23.9) 9.3 (4.9 − 26.7) 0.440
eGFR (ml/min/1.73m2) 91.8 ± 22.5 94.6 ± 22.1 91.8 ± 20.6 0.726
HOMA-IR 2.2 (1.2 − 3.7)b 2.5 (1.6 − 4.5)b,c 2.9 (1.7 − 5.3)c 0.027
Adiponectin (μg/ml) 9.1 ± 5.4 9.9 ± 7.3 8.5 ± 4.7 0.465
Mean IMT (mm) 0.66 ± 0.12b 0.67 ± 0.10b 0.73 ± 0.12 0.001
adifference among three groups.
b,cthe same letters indicate a statistically insignificant difference.
Jung et al. Cardiovascular Diabetology  (2015) 14:35 Page 4 of 8of diabetes, antidiabetic medications, percentage of sub-
jects taking antihypertensive medications or statins, levels
of total cholesterol, LDL-C, uric acid, AST, ALT, hsCRP,
UACR, eGFR, and total adiponectin, were similar among
the three groups (Table 1). FPG, HbA1c, TG, HOMA-IR,
and carotid IMT linearly increased (p value 0.047 to
0.001), while HDL-C decreased linearly across increasing
serum ANGPTL2 tertile categories (p = 0.036).
Table 2 shows the correlation between serum levels of
ANGPTL2 versus various glucometabolic parameters. In the
Pearson’s correlation analysis, the ANGPTL2 levels showeda positive correlation with AST (r= 0.222, p= 0.004), hsCRP
(r= 0.218, p = 0.011), HbA1c (r= 0.178, p= 0.022), and
HOMA-IR (r= 0.116, p= 0.045) following log transform-
ation of all four factors.
In the Pearson’s correlation analysis, the ANGPTL2
level was positively correlated with carotid IMT (r = 0.220,
p = 0.004, Figure 1). The correlation between serum
ANGPTL2 level and carotid IMT was significant even
after adjusting for age (r = 0.272, p < 0.001).
As shown in Table 3, multiple linear regression dem-
onstrated that serum ANGPTL2 [B (SE) = 0.012 (0.003);
Table 2 Correlation between serum levels of ANGPTL2
and glucometabolic parameters
ANGPTL2 (ng/ml)







Duration of diabetes −0.136 0.080












aLogarithmic transformation was performed. NS: not significant.
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(SE) = 0.005 (0.001); p < 0.001], male gender [(vs. female), B
(SE) = 0.060 (0.015); p < 0.001], and systolic BP [B (SE) =
0.001 (0.001); p = 0.016], were independently associated
with carotid IMT.
Finally, we examined the clinical and biochemical fac-
tors that contributed to the elevated serum ANGPTL2
concentrations in our subjects with type 2 diabetes. Mul-
tiple linear regression demonstrated that higher HbA1cFigure 1 Correlation between the serum ANGPLT2 concentrations
and carotid IMT (r = 0.220, p = 0.004).[B (SE) = 3.648 (1.789); p = 0.043] and hsCRP [B (SE) =
0.439 (0.196); p = 0.027] were significantly associated
with elevated serum ANGPTL2 concentrations in these
individuals (Additional file 1: Table S1).
Discussion
ANGPTL2 is a novel proinflammatory cytokine primar-
ily secreted by adipose tissues, although vascular endo-
thelial cells and monocyte/macrophages also secrete this
protein [9,10,13]. ANGPTL2 has been known to regulate
angiogenesis similarly to several other ANGPTLs [3,4].
In addition, ANGPTL2 has the unique capacity to in-
duce an inflammatory response in blood vessels as well
as in adipose tissue [9,10,12-14]. For instance, several ex-
perimental studies have suggested the biological rele-
vance of ANGPTL2 as a regulator of atherosclerosis in
rodents [9,10,12-14]. In our current study, the serum
ANGPTL2 concentration is significantly and positively
associated with carotid IMT in subjects with type 2 dia-
betes (r = 0.220, p < 0.01, Figure 1). Furthermore, this as-
sociation is independent of conventional cardiovascular
risk factors (Table 3). Considering the reported harmful
effects of ANGPTL2 on vascular inflammation in ro-
dents [9,10,12-14], our current findings provide further
evidence that this protein may play a key role in athero-
sclerosis in humans.
To date, there have been a few studies that have mea-
sured the serum ANGPTL2 concentrations in human
subjects [9,10,14,25-27] and investigated the differences
in these levels according to the presence of CVD
[9,10,14]. In 2009, Tabata et al. measured the serum
levels of ANGPTL2 in a total of 109 patients with cor-
onary heart disease (CHD) diagnosed by coronary angi-
ography and 89 drug-naïve type 2 diabetes patients [10].
These authors demonstrated that serum ANGPTL2 was
significantly increased in patients with CHD or type 2 dia-
betes [10]. More recently, Horio et al. demonstrated that
ANGPTL2 was abundantly expressed in atheromatous
plaques in human coronary artery, and that the circulating
ANGPTL2 levels measured by ELISA were higher in hu-
man subjects with CHD (defined by coronary artery sten-
osis ≥75% on coronary angiography; n = 89) compared
with age-matched non-CHD subjects (n = 30) [9]. Further-
more, they showed that serum ANGPTL2 levels were as-
sociated with carotid IMT in 359 seniors aged between 85
to 99 years with no history of CVD, but with relatively re-
duced eGFR (mean 62.5 ± 16.8 ml/min/1.73m2) and ad-
vanced stages of atherosclerosis (mean carotid IMT of
0.99 ± 0.15 mm compared with our current study measure-
ment of 0.69 ± 0.12 mm), among whom a small proportion
of subjects with diabetes was included (approximately
18.4%) [9]. Although these previous data support the hy-
pothesis that serum ANGPTL2 is strongly related to ath-
erosclerosis in humans, little is known whether this role of
Table 3 Multiple linear regression with the mean carotid IMT as a dependent variable
Univariate analysis Multivariate analysis
Variables β B (SE) P value β B (SE) P value
Age (years) 0.376 0.005 (0.001) <0.001 0.374 0.005 (0.001) <0.001
Male (vs. female) 0.235 0.054 (0.018) 0.002 0.257 0.060 (0.015) <0.001
BMI 0.093 0.003 (0.003) 0.234
WC 0.176 0.002 (0.001) 0.023
Systolic BP 0.242 0.002 (0.001) 0.002 0.165 0.001 (0.001) 0.016
Diastolic BP 0.177 0.002 (0.001) 0.023
Current smokera −0.009 −0.003 (0.023) 0.908
Duration of diabetes (years) 0.146 0.003 (0.001) 0.060
HTN medication useb 0.185 0.043 (0.018) 0.017
Statin useb −0.060 −0.016 (0.021) 0.443
FPG 0.076 0.000 (0.000) 0.329
HbA1cc 0.089 0.080 (0.070) 0.253
Total cholesterol −0.006 0.000 (0.000) 0.938
TGd −0.026 −0.006 (0.018) 0.737
LDL-C 0.000 0.000 (0.000) 0.995
HDL-C −0.048 0.000 (0.001) 0.538
Uric acid 0.162 0.014 (0.007) 0.037
ASTc 0.044 0.014 (0.024) 0.572
ALTc 0.051 0.011 (0.016) 0.511
hsCRPc 0.057 0.006 (0.009) 0.513
UACRc −0.004 0.000 (0.007) 0.958
eGFR −0.153 −0.001 (0.000) 0.049
HOMA-IRc −0.029 −0.003 (0.010) 0.730
Adiponectin −0.095 −0.002 (0.002) 0.224
Serum ANGPTL2 0.220 0.010 (0.003) 0.004 0.263 0.012 (0.003) <0.001
β: standardized coefficient, B: unstandardized coefficient, SE: standard error.
avs. noncurrent smoker.
bvs. nonuser.
cLogarithmic transformation was performed.
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in subject with early stage atherosclerosis. Our current
evidence may suggest the independent involvement of
ANGPTL2 in the pathogenesis of early subclinical athero-
sclerosis in humans, especially in subjects with type 2 dia-
betes. This role of ANGPTL2 in early atherosclerosis
accords with the findings of a previous animal study, in
which ANGPTL2 altered the release of nitric oxide, an
important anti-atherogenic molecule [28], leading to
endothelial dysfunction at stages of atherosclerosis pre-
ceding atherosclerotic plaque formation [9,14]
In humans, the ANGPTL2 concentration in the circula-
tion is up-regulated in obesity (particularly visceral obes-
ity) and is correlated with the levels of systemic insulin
resistance [10,25]. In accordance with these previous re-
sults [10,25], biochemical variables indicating insulin-
resistant profiles such as higher TG and HOMA-IR andlower HDL-C could be seen across increasing serum
ANGPTL2 tertile categories in our present analyses
(Table 1). In addition, we found a significant positive cor-
relation between serum ANGPTL2 concentration and
AST, hsCRP, and HOMA-IR (Table 2). Our current find-
ings thus support the previously suggested possibility that
circulating ANGPTL2 levels can serve as a marker of
obesity-induced metabolic abnormalities as well as athero-
sclerosis [10,25,29].
There have been conflicting results regarding the role
of ANGPTL2 in glucose metabolism [10,30]. In a previ-
ous study using ANGPTL2 knock-out mice, insulin sen-
sitivity was improved in both the skeletal muscle and
liver in mice fed with a high-fat diet [10]. In contrast,
the replenishment of ANGPTL2 stimulated insulin sen-
sitivity and improved glucose tolerance in mice [30]. In
our current study, glycemic variables including FPG and
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increased (Table 1), and there was a positive correlation
observed between the serum ANGPTL2 concentration
and HbA1c (Table 2), which are in line with the results
of a previous study [25]. Furthermore, we observed that
HbA1c is one of the independent contributors to the in-
creased serum ANGPTL2 concentration (Additional file
1: Table S1). Recently, Doi et al. firstly demonstrated that
elevated serum ANGPTL2 levels were positively associ-
ated with the development of type 2 diabetes in a total
of 2,164 community-dwelling Japanese individuals, inde-
pendent of other risk factors including hsCRP levels
[31]. In that analysis, the risk of developing type 2 dia-
betes was significantly higher in the highest ANGPTL2
quartile (i.e., ≥ 3.41 ng/ml) than in the lowest quartile
(hazard ratio, 1.80) [31]. Although further studies are
needed to reveal the role of ANGPTL2 in the pathogen-
esis of type 2 diabetes, these earlier results and our
present findings suggest the possibility that ANGPTL2
might be one of key mediators that link obesity and type
2 diabetes.
It is well accepted that obesity can be regarded as a
state of chronic subclinical inflammation [32-34], and
levels of hsCRP, a marker of low-grade inflammation,
have been previously linked to visceral obesity [35,36].
The liver is assumed to be the major source of CRP pro-
duction; however, adipose tissues have also been sug-
gested as a direct source of CRP [37,38]. In our current
study, the serum ANGPTL2 concentration showed a sig-
nificant correlation with hsCRP (Table 2), and hsCRP
was one of the independent contributors to the in-
creased serum ANGPTL2 concentration (Additional file
1: Table S1), which are in accordance with the results of
a previous study [10]. This close relationship between
ANGPTL2 and hsCRP further implicates that ANGPTL2
is one of key adipocyte-derived inflammatory mediators
linking obesity to related metabolic diseases.
This study has several noteworthy limitations. First, our
sample size was not large enough to make any definite con-
clusions. This limitation was partly reflected in the results
of our study, in which there was an insignificant inverse
correlation between the levels of total serum adiponectin
and ANGPTL2 (r = −0.096, p = 0.235 in Table 2), which is
in contrast to the results of a previous study showing a sig-
nificant association between these two factors [39]. Second,
we lacked data on other inflammatory markers of systemic
inflammation besides hsCRP. Additional markers reflecting
adipose tissue dysfunction such as IL-6 would significantly
strengthen the findings of this study [40]. Third, due to the
cross-sectional design of our present study, we could not
assess the temporal relationship between the serum
ANGPTL2 level and increased carotid atherosclerosis.
Fourth, because we included only Korean subjects, our re-
sults may not be applicable to other ethnic populations.Despite these limitations, our current study is mean-
ingful in that we demonstrated the relationships between
serum ANGPTL2 concentration and early subclinical
atherosclerosis in humans, especially in subjects with
type 2 diabetes.
Conclusions
In conclusion, we found that the serum ANGPTL2 concen-
tration is significantly and positively associated with carotid
IMT in human subjects with type 2 diabetes. This further
supports the recently proposed notion that ANGPTL2 may
be an important factor in the pathogenesis of atheroscler-
osis in humans [9,10,14], similarly to its possible role in the
regulation of vascular function in rodents [9,10,12-14]. Fur-
ther prospective studies are needed to determine whether
ANGPTL2 is a useful predictive marker for CVD.
Additional file
Additional file 1: Table S1. Univariate and multivariate analysis of the
relationship between the serum ANGPTL2 concentrations and various
clinical parameters.
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